Clinical trials
BRCA2 Mutation clinical trials
Below are recruiting brca2 mutation clinical trials, each written for real people, not researchers. We’re tracking 23 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05420064Recruiting
Help with family cancer gene testing and unclear results
This trial helps people and their doctors understand and act on genetic test results, including when results are uncertain. It tests whether a structured approach improves who gets tested in families and helps patients and primary care providers stay up-to-date.
Basking Ridge, New JerseyAges 25 years+ - NCT06177171RecruitingPhase 1
Olaparib and ASTX727 for DNA repair-deficient cancers
This trial tests a combination of two drugs—olaparib (a PARP inhibitor) and ASTX727 (a DNA hypomethylating agent)—for people whose cancers have a specific DNA repair flaw. The goal is to see if this combination can shrink tumors or slow their growth.
San Francisco, CaliforniaAges 18 years+ - NCT05898009Recruiting
Study BRCA2 gene changes in breast cancer in Reunion
This study looks at how often certain BRCA2 gene changes occur in people in Réunion who have breast cancer. Your participation may help doctors understand breast cancer risk in the local community and guide future care.
Saint-PierreAges 18 years+ - NCT05694715RecruitingPhase 1
Test combo treatment for cancers with DNA repair gene mutations
This Phase 1 study tests a combination of medicines (including niraparib and irinotecan) for advanced solid tumors that have specific DNA repair gene changes, such as BRCA1/2 or related defects. It aims to see whether the treatment can shrink tumors and is safe enough to continue studying.
San Francisco, CaliforniaAges 18 years+ - NCT05485766RecruitingPhase 2
Pembrolizumab with cancer medicines for BRCA-mutated triple negative breast cancer
This Phase 2 trial studies a treatment plan given before surgery (neoadjuvant) and after surgery (adjuvant) for people with BRCA1/2-mutated triple negative breast cancer that has not spread. It aims to improve how well the cancer responds and how long people stay cancer-free.
Gifu, GifuAges 18 years+ - NCT04294927Recruiting
Tube removal first, then ovaries later for high-risk women
This study looks at whether removing the fallopian tubes first, and the ovaries later, is safe for women with certain inherited gene mutations that raise ovarian cancer risk. It may help you understand a prevention approach when you’re considered high risk and have finished having children.
Chicago, IllinoisAges 25–50 - NCT05129605Recruiting
Prostate cancer genetic risk screening study for men
This study looks at your personal and family risk for prostate cancer and helps decide who should have extra screening like MRI. It may help you find cancer earlier if you are at higher genetic risk.
Boston, MassachusettsAges 35–74 - NCT03702309Recruiting
Banking and testing blood samples to study cancer
This study collects blood samples to “test and store” (bank) information that may help doctors understand cancer in the future. You might be able to join if you’re an adult with confirmed cancer or a higher-than-usual risk for cancer.
Toronto, OntarioAges 18 years+ - NCT07253051Recruiting
Study for women with BRCA gene mutations
This study creates a platform for women who carry a BRCA1 or BRCA2 gene mutation to be followed over time. It aims to better understand and manage cancer risks associated with these mutations.
AvellinoAges 18 years+ - NCT06488378RecruitingPhase 1
Axatilimab and olaparib for BRCA/PALB2-mutated breast cancer
This trial tests combining two drugs – axatilimab and olaparib (a PARP inhibitor) – for people with advanced HER2-negative breast cancer that carries a BRCA or PALB2 gene mutation. The goal is to see if this new combination is safe and effective.
Boston, MassachusettsAges 18 years+ - NCT06972719Recruiting
Hormone therapy after ovary removal for BRCA mutation carriers
This study looks at giving hormone therapy after ovary and fallopian tube removal in women with a BRCA mutation. The goal is to help manage menopause symptoms while you are still premenopausal.
Chapel Hill, North CarolinaAges 19–50 - NCT04095195Recruiting
Pancreatic cancer risk registry for high-risk families
This study builds a registry of people with a higher-than-average risk of pancreatic cancer, based on family history or inherited gene conditions. If you join the extra imaging follow-up, it helps your care team monitor risk earlier.
Rozzano, MilanAges 18–80 - NCT04150042RecruitingPhase 1
Test of chemotherapy plus your own stem cells for metastatic cancer
This Phase 1 trial tests a treatment approach using standard chemotherapy along with stem cells taken from you to treat metastatic pancreatic or breast cancer. It is mainly designed to check safety and find the best way to give the treatment, and it may offer an option for people whose cancer has spread.
Boston, MassachusettsAges 18 years+ - NCT06201234RecruitingPhase 2
Adding elacestrant to olaparib for advanced HR+/HER2- breast cancer
This trial tests if adding a new oral medicine (elacestrant) to a standard PARP inhibitor (olaparib) works better for people with advanced or metastatic HR+/HER2- breast cancer who have a BRCA1 or BRCA2 gene mutation. The goal is to see if the combination can help control the cancer longer.
Stuttgart, Baden-WurttembergAges 18 years+ - NCT06817694Recruiting
CBT for fear of cancer returning in BRCA1/2 women
This trial tests if cognitive behavioral therapy can reduce fear of cancer recurrence in women with BRCA1/2 mutations who have finished treatment for breast or ovarian cancer. It aims to help you cope with worries about cancer coming back.
Québec, QuebecAges 18 years+ - NCT03544983Enrolling by invitation
Genetic education program for BRCA family members
This trial offers education about BRCA1 and BRCA2 gene mutations to help families understand testing, cancer risk, and next steps. It may be helpful if you are a family member of someone who recently learned they have a BRCA mutation.
Washington D.C., District of ColumbiaAges 21–75 - NCT04090567RecruitingPhase 2
Olaparib with two partners for advanced BRCA breast cancer
This trial tests whether the drug olaparib works better when combined with cediranib or AZD6738 in people with advanced or metastatic BRCA (inherited) breast cancer. It may help shrink tumors or slow cancer growth after prior treatment with a PARP inhibitor.
Houston, TexasAges 18 years+ - NCT07436312Recruiting
Effect of ultra-processed foods on cancer risk in high-risk people
This trial looks at whether eating less ultra-processed foods can lower cancer risk in people who are already at high risk for cancer. It is part of a larger program called Interception that helps monitor and reduce cancer risk.
AvignonAges 18 years+ - NCT06395519RecruitingPhase 1/Phase 2
Study of ETX-19477 for advanced solid tumors
This trial tests an experimental drug called ETX-19477 for people with advanced solid tumors that have stopped responding to other treatments. It aims to see if the drug is safe and effective, especially for those with certain genetic changes (BRCA2 mutations).
Phoenix, ArizonaAges 18 years+ - NCT05806515RecruitingPhase 2
Carboplatin before surgery for high-risk BRCA prostate cancer
This trial tests giving the chemotherapy drug carboplatin before surgery to treat people with high-risk prostate cancer and an inherited BRCA1 or BRCA2 gene change. The goal is to shrink or control the cancer before an operation and improve outcomes.
Anchorage, AlaskaAges 18 years+ - NCT04858334RecruitingPhase 2
Olaparib after pancreatic cancer surgery for BRCA or PALB2 mutations
This trial studies whether olaparib (a targeted cancer medicine) can help prevent pancreatic cancer from coming back after surgery in people with BRCA1, BRCA2, or PALB2 mutations. You would get olaparib or a placebo (inactive pill) and be closely followed to see if recurrence is reduced.
Anchorage, AlaskaAges 18 years+ - NCT07498829Recruiting
Cancer risk genetic testing for people with female organs
This study offers free genetic testing to women, trans men, and non-binary people (with female reproductive organs) who have not had previous testing for certain cancer-related genes. It aims to find people at higher risk for cancer so they can take steps to prevent it or catch it early.
LondonAges 18 years+ - NCT04038502RecruitingPhase 2
Testing carboplatin or olaparib for gene-linked prostate cancer
This Phase 2 study tests whether carboplatin or olaparib can help people with prostate cancer that has certain DNA repair gene changes. It’s designed for advanced (metastatic) prostate cancer that is growing despite standard hormone-blocking treatment.
West Los Angeles, CaliforniaAges 18 years+
Hear when a new BRCA2 Mutation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
BRCA2 Mutation trials by city
Studies with a site in or near these metro areas.
BRCA2 Mutation trials by state
Studies with a site anywhere in these states.
Common questions
- Are there clinical trials for brca2 mutation?
- Yes. Clin2 currently lists 23 recruiting brca2 mutation studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a brca2 mutation trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a brca2 mutation trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.